BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16299344)

  • 1. Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.
    Yauch LE; Mansour MK; Levitz SM
    Infect Immun; 2005 Dec; 73(12):8429-32. PubMed ID: 16299344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo.
    Yauch LE; Mansour MK; Shoham S; Rottman JB; Levitz SM
    Infect Immun; 2004 Sep; 72(9):5373-82. PubMed ID: 15322035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
    Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
    J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
    Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
    Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.
    Chang ZL; Netski D; Thorkildson P; Kozel TR
    Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1.
    De Jesus M; Park CG; Su Y; Goldman DL; Steinman RM; Casadevall A
    Med Mycol; 2008 Mar; 46(2):153-62. PubMed ID: 18324494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
    Yauch LE; Lam JS; Levitz SM
    PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dectin-3 Recognizes Glucuronoxylomannan of
    Huang HR; Li F; Han H; Xu X; Li N; Wang S; Xu JF; Jia XM
    Front Immunol; 2018; 9():1781. PubMed ID: 30131805
    [No Abstract]   [Full Text] [Related]  

  • 9. Receptor-mediated recognition of Cryptococcus neoformans.
    Levitz SM
    Nihon Ishinkin Gakkai Zasshi; 2002; 43(3):133-6. PubMed ID: 12145626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
    Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
    Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R; Lees A; Pirofski L
    J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.
    De Jesus M; Nicola AM; Rodrigues ML; Janbon G; Casadevall A
    Eukaryot Cell; 2009 Jan; 8(1):96-103. PubMed ID: 18952901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The heat shock protein (Hsp) 70 of Cryptococcus neoformans is associated with the fungal cell surface and influences the interaction between yeast and host cells.
    Silveira CP; Piffer AC; Kmetzsch L; Fonseca FL; Soares DA; Staats CC; Rodrigues ML; Schrank A; Vainstein MH
    Fungal Genet Biol; 2013 Nov; 60():53-63. PubMed ID: 23954835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.
    Nimrichter L; Frases S; Cinelli LP; Viana NB; Nakouzi A; Travassos LR; Casadevall A; Rodrigues ML
    Eukaryot Cell; 2007 Aug; 6(8):1400-10. PubMed ID: 17573547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.
    Albuquerque PC; Fonseca FL; Dutra FF; Bozza MT; Frases S; Casadevall A; Rodrigues ML
    Future Microbiol; 2014; 9(2):147-61. PubMed ID: 24571070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan.
    Albuquerque PC; Cordero RJ; Fonseca FL; Peres da Silva R; Ramos CL; Miranda KR; Casadevall A; Puccia R; Nosanchuk JD; Nimrichter L; Guimaraes AJ; Rodrigues ML
    Fungal Genet Biol; 2012 Nov; 49(11):943-54. PubMed ID: 23010152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoregulation by capsular components of Cryptococcus neoformans.
    Vecchiarelli A
    Med Mycol; 2000 Dec; 38(6):407-17. PubMed ID: 11204878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan in patients after solid-organ transplantation.
    Jalali Z; Ng L; Singh N; Pirofski LA
    Clin Vaccine Immunol; 2006 Jul; 13(7):740-6. PubMed ID: 16829610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat.
    Goldman D; Lee SC; Casadevall A
    Infect Immun; 1994 Nov; 62(11):4755-61. PubMed ID: 7927751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.